CAS 882697-00-9

3-(2H-1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole

CAS: 882697-00-9

Fórmula: C₁₆H₁₁BrN₂O₂

Pureza: 98%

Cor e Forma: Solid

Peso molecular: 343.1747

Ref: IN-DA01C02Q

3-(Benzo[D][1,3]Dioxol-5-Yl)-5-(3-Bromophenyl)-1H-Pyrazole

CAS: 882697-00-9

3-(Benzo[D][1,3]Dioxol-5-Yl)-5-(3-Bromophenyl)-1H-Pyrazole

Pureza: 98%

Peso molecular: 343.17g/mol

Ref: 54-OR1023233

Anle138b

CAS: 882697-00-9

Anle138b

Pureza: ≥98%

Peso molecular: 343.17g/mol

Ref: 54-BUP13852

Anle138b

CAS: 882697-00-9

Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease

Fórmula: C₁₆H₁₁BrN₂O₂

Pureza: 98.88% - 99.82%

Cor e Forma: Solid

Peso molecular: 343.17

Ref: TM-T5447

Anle 138b

Produto Controlado

CAS: 882697-00-9

Applications Anle 138b is an anti-aggregating compound previously shown to delay the onset of scrapie, a transmissible prion disease. A protein aggregation inhibitor.
References Qin, K., et al.: J. Gen. Virol., 100, 1027 (2019); Matthes, D., et al.: ACS Chem. Neurosci., 8, 2791 (2017); Wagner, J., et al.: Acta Neuropathol.,130, 619 (2015)

Fórmula: C₁₆H₁₁BrN₂O₂

Cor e Forma: Neat

Peso molecular: 343.175

Ref: TR-A648250

Anle138b

CAS: 882697-00-9

Anle138b is a cyclic lipopeptide that belongs to the group of photochemically active substances. It has been shown to be effective in a number of animal models, including a model system for Alzheimer's disease, and has been shown to be clinically relevant in humans. Anle138b is being investigated as a treatment for cognitive impairment due to its ability to cross the blood-brain barrier and bind selectively to neurons. The drug has been shown to inhibit synaptic dysfunction and energy metabolism in these cells. Clinical trials are ongoing for Alzheimer's disease and other dementias.

Fórmula: C₁₆H₁₁BrN₂O₂

Pureza: Min. 95%

Peso molecular: 343.17 g/mol

Ref: 3D-HKB69700